SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems
MWN-AI** Summary
SOPHiA GENETICS, a leading player in AI-driven precision medicine, announced a significant expansion in the United States with the addition of two major integrated health systems to its network. The partnership includes a prominent nonprofit, multi-region healthcare system and a top 10 health system laboratory. Collectively, these institutions handle millions of genetic samples each year and will leverage SOPHiA's innovative cloud-based platform, SOPHiA DDM™, to enhance genomic data analysis.
The initial phase of this collaboration aims to provide genomic testing for approximately 60,000 patients annually across the West Coast and Midwest. This initiative is designed to facilitate quicker diagnoses and enable more personalized care for individuals suffering from hereditary cancers and rare diseases. Utilizing the Enhanced Exome application within SOPHiA DDM™, the health systems will conduct comprehensive analyses of over 20,000 genes, allowing for deeper exploration of clinically significant regions of the genome.
John Carey, Managing Director of North America for SOPHiA GENETICS, emphasized that the partnership highlights the increasing demand for scalable AI-powered genomic solutions. This collaboration aims to combine advanced bioinformatics with a global knowledge community to derive actionable insights that can accelerate healthcare innovation.
As the newest members of SOPHiA's network, the two health systems together serve nearly one million patients with cancer and rare disorders each year, positioning them to expand their research and operational capabilities significantly. This expansion underscores SOPHiA GENETICS' commitment to democratizing data-driven medicine and enhancing research opportunities across the healthcare landscape. The company continues to fortify its presence in the U.S. as it strives to transform patient care through innovative technology.
MWN-AI** Analysis
SOPHiA GENETICS (NASDAQ: SOPH) has recently made significant strides in its U.S. operations by signing partnerships with two major integrated health systems, a move that could catalyze substantial growth for the company. This expansion allows SOPHiA to leverage its AI-driven SOPHiA DDM™ platform to analyze millions of genetic samples, specifically targeting areas such as hereditary cancers and rare diseases.
For investors, this development is a clear indicator of SOPHiA’s commitment to scaling its operations in a lucrative market that increasingly demands precision medicine solutions. With the ability to process genomic data at an unprecedented scale, these partnerships not only enhance the company’s service offerings but also position SOPHiA to play a pivotal role in advancing personalized healthcare.
The partnership is set to initially service up to 60,000 patients annually, reflecting a robust demand for genomic testing that is expected to grow. Investors should take note of the potential revenue growth that could derive from these contracts, particularly as healthcare systems globally pivot towards data-driven approaches. Given that the company is addressing complex use cases in genomic medicine with potential high margins, this could enhance profitability.
However, while the expansion presents opportunities, it is essential to remain vigilant regarding the execution risks associated with operational scalability. The competitive landscape in advanced genomics is intensifying, with various players also innovating in AI and data solutions. As such, stakeholders should monitor SOPHiA's ability to maintain its technological edge and market position.
Overall, SOPHiA GENETICS’ strategic expansion is likely to enhance its growth trajectory and solidify its standing within the healthcare sector. Investors may want to consider initiating or increasing positions in SOPH, as the ongoing demand for genomic solutions continues to rise.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network.
The two new institutions, which collectively analyze millions of genetic samples annually, include one of the leading nonprofit, multi-region integrated healthcare systems in the U.S. and a top 10 U.S. health system laboratory. Together, these institutions will leverage the AI-native, cloud-based SOPHiA DDM™ to analyze complex genomic data at scale.
By adopting SOPHiA DDM™, the two institutions will initially launch genomic testing for up to 60,000 patients annually across the West Coast and Midwest, enabling faster diagnosis and more personalized care for individuals living with hereditary cancers and rare diseases.
Both health systems will utilize SOPHiA DDM™ for Enhanced Exome, an AI-driven analytics application that supports comprehensive full-exome analysis for over 20,000 genes while enabling the ability to dive deeper into clinically relevant regions. With these capabilities directly embedded into their laboratory workflows, the institutions aim to expedite testing turnaround times, streamline operational costs, and expand internal research and innovation initiatives.
John Carey, Managing Director, North America, SOPHiA GENETICS, said: "Partnering with two of the largest health systems in the U.S. underscores the growing need for AI-powered genomic solutions capable of addressing increasingly complex use cases that can scale without adding operational burden. Combining advanced bioinformatics, the collective knowledge of a global community, and streamlined workflows, our AI enables healthcare institutions to unlock deeper insights."
Going forward, this collaboration positions both organizations with a scalable foundation to support future expansion of AI-driven precision medicine. Each year, these organizations serve a combined population of nearly one million cancer and rare disorder patients nationwide.
SOPHiA GENETICS continues to strengthen its presence in the United States while supporting leading healthcare institutions across some of the most complex areas of precision medicine. The expansion in the region reinforces the company's mission to democratize data-driven medicine by equipping researchers and clinicians with AI-powered solutions that accelerate healthcare innovation and research.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to the company's management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company's filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company's expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
SOURCE SOPHiA GENETICS
FAQ**
How will the expansion of SOPHiA GENETICS SA SOPH into major U.S. health systems impact its growth trajectory and market position in the precision medicine sector?
What specific AI-driven capabilities will SOPHiA GENETICS SA SOPH's SOPHiA DDM™ platform provide to the newly partnered health systems in terms of genomic data analysis?
Given the emphasis on personalized care, how does SOPHiA GENETICS SA SOPH plan to measure the effectiveness and outcomes of genomic testing for the 60,000 patients annually?
What potential operational challenges might SOPHiA GENETICS SA SOPH face in scaling its solutions while partnering with large integrated health systems?
**MWN-AI FAQ is based on asking OpenAI questions about SOPHiA GENETICS SA (NASDAQ: SOPH).
NASDAQ: SOPH
SOPH Trading
2.67% G/L:
$4.5481 Last:
92,891 Volume:
$4.50 Open:
